FOLH1 and metastatic prostate carcinoma: In end-stage castrate-resistant metastatic prostate cancer (mCRPC) patients, [177Lu]Lu-PSMA-617 [7–19] and/or [225Ac]Ac-PSMA-617 [20–24] showed remarkable responses with, in general, a mild toxicity profile.